

Supplemental Table 2. All Factors Examined for Prediction of Remission of Chronic Anterior Uveitis (Hazard Ratios Less than 1 are Unfavorable, Indicating a Lower Incidence of Remission); Conservative Analysis.†

		Crude		Adjusted*	
		Hazard Ratio (95% CI)	p	Hazard Ratio (95% CI)	p
Age at presentation	<40	Ref	<0.001	Ref	0.17
	40+	1.61 (1.26, 2.04)		1.22 (0.92, 1.63)	
Sex	Male	Ref	0.93	Ref	0.65
	Female	0.99 (0.77, 1.27)		1.06 (0.82, 1.38)	
Race category	White	Ref	0.69	Ref	0.70
	Black	0.83 (0.59, 1.17)		0.81 (0.56, 1.16)	
	Hispanic	0.78 (0.40, 1.54)		1.03 (0.52, 2.05)	
	Other	0.95 (0.69, 1.33)		0.93 (0.66, 1.32)	
Smoking	Never	Ref	0.93	Ref	0.18
	Past	1.04 (0.71, 1.53)		0.85 (0.56, 1.30)	
	Current	0.92 (0.63, 1.35)		0.69 (0.45, 1.06)	
	Unknown	0.88 (0.52, 1.48)		0.61 (0.32, 1.14)	
Bilateral	No	Ref	0.41	Ref	0.48
	Yes	0.88 (0.65, 1.19)		0.90 (0.66, 1.22)	
Duration of uveitis prior to presentation	<6 Months	Ref	<0.001	Ref	0.009
	6 Months to <2 Years	0.83 (0.61, 1.13)		0.79 (0.57, 1.09)	
	2 to <5 Years	0.52 (0.36, 0.75)		0.56 (0.38, 0.81)	
	5+ Years	0.56 (0.41, 0.77)		0.65 (0.46, 0.91)	
Prior cataract surgery	No	Ref	0.15	Ref	0.08
	Yes	0.84 (0.65, 1.07)		0.79 (0.60, 1.03)	
Pars Plana Vitrectomy (not Ret Detach)	No	Ref	0.055	Ref	0.52
	Yes	0.61 (0.36, 1.01)		0.84 (0.50, 1.42)	
Any glaucoma surgery	No	Ref	0.053	Ref	0.08
	Yes	0.70 (0.49, 1.00)		0.70 (0.47, 1.05)	
Inflammatory activity at baseline	Inactive	Ref	0.16	Ref	0.96
	Slightly active	1.14 (0.81, 1.60)		1.03 (0.67, 1.60)	
	Active	0.84 (0.65, 1.08)		1.06 (0.72, 1.58)	

		Crude		Adjusted*	
		Hazard Ratio (95% CI)	p	Hazard Ratio (95% CI)	p
Anterior chamber cells at baseline	Quiet	Ref	0.009	Ref	0.01
	0.5+	1.28 (0.97, 1.70)		1.34 (1.00, 1.79)	
	1+	0.81 (0.58, 1.12)		0.81 (0.58, 1.14)	
	≥2+	0.74 (0.54, 1.02)		0.83 (0.59, 1.17)	
Vitreous cells at baseline	Quiet	Ref	0.33	Ref	0.40
	0.5+	1.18 (0.80, 1.74)		1.08 (0.69, 1.69)	
	1+	0.76 (0.50, 1.16)		0.72 (0.46, 1.13)	
	≥2+	0.78 (0.47, 1.32)		0.74 (0.40, 1.35)	
Keratic precipitates	No	Ref	<0.001	Ref	<0.001
	Yes	0.27 (0.14, 0.53)		0.27 (0.14, 0.53)	
Band Keratopathy	No	Ref	<0.001	Ref	0.17
	Yes	0.42 (0.28, 0.62)		0.74 (0.48, 1.14)	
Synechia	Neither	Ref	<0.001	Ref	0.003
	Peripheral Synechia Only	0.76 (0.39, 1.46)		0.71 (0.34, 1.50)	
	Posterior Synechia Only	0.56 (0.43, 0.74)		0.62 (0.46, 0.82)	
	Posterior and Peripheral Synechia	0.49 (0.29, 0.81)		0.54 (0.32, 0.91)	
Macular Edema	No	Ref	0.40	Ref	0.62
	Yes	0.81 (0.51, 1.31)		1.13 (0.70, 1.83)	
Sarcoidosis	No	Ref	0.74	Ref	0.51
	Yes	1.07 (0.72, 1.60)		0.87 (0.56, 1.33)	
Juvenile Idiopathic Arthritis	No	Ref	<0.001	Ref	<0.001
	Yes	0.40 (0.28, 0.57)		0.42 (0.28, 0.64)	
Spondyloarthropathy	No	Ref	0.002	Ref	<0.001
	Yes	0.48 (0.30, 0.77)		0.42 (0.26, 0.69)	
HLAB27	No	Ref	0.23	Ref	0.58
	Yes	0.82 (0.59, 1.13)		1.11 (0.77, 1.60)	
Behçet Disease	No	Ref	0.85	Ref	0.36
	Yes	1.07 (0.51, 2.24)		0.63 (0.23, 1.70)	

		Crude		Adjusted*	
		Hazard Ratio (95% CI)	p	Hazard Ratio (95% CI)	p
Systemic Lupus	No	Ref	0.13	Ref	0.17
	Yes	0.24 (0.04, 1.55)		0.29 (0.05, 1.69)	
Diabetes	No	Ref	0.01	Ref	0.40
	Yes	1.65 (1.12, 2.44)		1.21 (0.78, 1.87)	
Hypertension	No	Ref	<0.001	Ref	0.29
	Yes	1.55 (1.20, 1.99)		1.19 (0.86, 1.65)	
Hyperlipidemia	No	Ref	<0.001	Ref	0.04
	Yes	1.82 (1.34, 2.47)		1.44 (1.02, 2.03)	
Statins ≥90 days	No	Ref	0.006	Ref	0.37
	Yes	1.76 (1.18, 2.64)		1.23 (0.78, 1.92)	
ACE Inhibitors ≥90 days	No	Ref	0.01	Ref	0.31
	Yes	1.73 (1.12, 2.68)		1.29 (0.79, 2.10)	
Aspirin ≥90 days	No	Ref	0.01	Ref	0.38
	Yes	1.95 (1.17, 3.26)		1.27 (0.74, 2.19)	

† To be considered in remission in the conservative analysis, eyes had to be completely inactive while not taking any medications at visits spanning 90 days or more; eyes quiet at the last visit who were not observed again over a period of at least 90 days were censored.

* Adjusted for age at presentation, bilateral, duration of uveitis prior to presentation, prior cataract surgery, any glaucoma surgery, anterior chamber cells at baseline, keratic precipitates, synechia, juvenile idiopathic arthritis, spondyloarthritis